Agonistic Antibody

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
Ben Tran, Richard D. Carvajal, Aurelien Marabelle, Sandip Pravin Patel, Patricia M. LoRusso, Erik Rasmussen, Gloria Juan, Vijay V. Upreti, Courtney Beers, Gataree Ngarmchamnanrith, Patrick Schöffski

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 93; DOI: 10.1186/s40425-018-0407-x
Murinization of an anti-GITR IgG2c antibody DTA-1 inhibits immunogenicity-mediated anaphylaxis in C57BL/6J mice
Hamsell Alvarez, Nicole Belmar, Melvin Fox, Josue Samayoa, Sarah Chan, Diane Hollenbaugh, Fiona Harding

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P182; DOI: 10.1186/2051-1426-3-S2-P182
The use of anti-GITR antibody treatment in a murine model of glioblastoma multiforme
Jason Miska, Alan L Chang, Aida Rashidi, Mahua Dey, Yu Han, Lingjiao Zhang, Irina V Balyasnikova, Atique U Ahmed, Maciej S Lesniak

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P236; DOI: 10.1186/2051-1426-3-S2-P236
Pharmacodynamic analysis of an agonistic antibody to the costimulatory receptor GITR
Gordon Moody, Jodi Moriguchi, Ji-Rong Sun, Patricia McElroy, Hong Tan, Yannick Bulliard, Beltran Pedro

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P192; DOI: 10.1186/2051-1426-3-S2-P192
The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities
Pia Bjorck, Erin Filbert, Yongke Zhang, Xiaodong Yang, Ovid Trifan

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P198; DOI: 10.1186/2051-1426-3-S2-P198

Log in using your username and password

Main menu

Log in using your username and password

You are here

Agonistic Antibody